These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 22023894)

  • 1. Duration of treatment in postmenopausal osteoporosis: how long to treat and what are the consequences of cessation of treatment?
    Laster AJ; Tanner SB
    Rheum Dis Clin North Am; 2011 Aug; 37(3):323-36, v. PubMed ID: 22023894
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical strategies to address patients' concerns in osteoporosis management with bisphosphonates.
    Cole RE
    Postgrad Med; 2011 Mar; 123(2):131-44. PubMed ID: 21474901
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fracture risk reduction during treatment with teriparatide is independent of pretreatment bone turnover.
    Delmas PD; Licata AA; Reginster JY; Crans GG; Chen P; Misurski DA; Wagman RB; Mitlak BH
    Bone; 2006 Aug; 39(2):237-43. PubMed ID: 16563890
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevention and management of osteoporosis: consensus statements from the Scientific Advisory Board of the Osteoporosis Society of Canada. 3. Effects of ovarian hormone therapy on skeletal and extraskeletal tissues in women.
    Josse RG
    CMAJ; 1996 Oct; 155(7):929-34. PubMed ID: 8837542
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of osteoporosis in postmenopausal women: 2010 position statement of The North American Menopause Society.
    Menopause; 2010; 17(1):25-54; quiz 55-6. PubMed ID: 20061894
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [How to prevent early postmenopausal fracture risk? Proposition of a strategy].
    Trémollieres F; Pouilles JM; Ribot C
    Gynecol Obstet Fertil; 2009 Jan; 37(1):50-6. PubMed ID: 19110461
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Calcium pros and cons: long term use of bisphosphonates. Bisphosphonates should be used for postmenopausal osteoporosis for a long term].
    Soen S
    Clin Calcium; 2011 Oct; 21(10):1543-6. PubMed ID: 21960242
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Strategies for treatment to prevent fragility fractures in postmenopausal women.
    Geusens P
    Best Pract Res Clin Rheumatol; 2009 Dec; 23(6):727-40. PubMed ID: 19945685
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis and treatment of osteoporosis.
    Sweet MG; Sweet JM; Jeremiah MP; Galazka SS
    Am Fam Physician; 2009 Feb; 79(3):193-200. PubMed ID: 19202966
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Therapeutic concepts in the treatment of postmenopausal osteoporosis].
    Leidig-Bruckner G; Ziegler R
    Ther Umsch; 1994 Nov; 51(11):737-47. PubMed ID: 7839332
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Strontium: new drug. Postmenopausal osteoporosis: too many unknowns.
    Prescrire Int; 2005 Dec; 14(80):207-11. PubMed ID: 16397977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What to do about postmenopausal fracture risk. Diet, exercise, calcium, and vitamin D are always important, but women at high risk for fractures may need drug therapy, too.
    Harv Womens Health Watch; 2009 Dec; 17(4):1-3. PubMed ID: 20088086
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
    Iwamoto J; Takeda T; Sato Y
    Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Current approaches to the diagnosis and treatment of postmenopausal osteoporosis].
    Baranova IA
    Ter Arkh; 2009; 81(10):56-60. PubMed ID: 19947443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. New possibilities for diagnosis and treatment of osteoporosis.
    Miller PD
    Int J Fertil Womens Med; 2001; 46(4):215-21. PubMed ID: 11563832
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Osteoporotic fracture in menopausal women: alendronate reduces the risk].
    Bize R; Lamy O; Peytremann-Bridevaux I
    Rev Med Suisse; 2008 Dec; 4(183):2703. PubMed ID: 19157286
    [No Abstract]   [Full Text] [Related]  

  • 17. Osteoporosis in postmenopausal women. Therapy options across a wide range of risk for fracture.
    Miller RG
    Geriatrics; 2006 Jan; 61(1):24-30. PubMed ID: 16405361
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Characterization of patients with an inadequate clinical outcome from osteoporosis therapy: the Observational Study of Severe Osteoporosis (OSSO).
    Jakob F; Marín F; Martín-Mola E; Torgerson D; Fardellone P; Adami S; Thalassinos NC; Sykes D; Melo-Gomes J; Chinn C; Nicholson T; Cooper C
    QJM; 2006 Aug; 99(8):531-43. PubMed ID: 16861718
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bone anabolic versus bone anticatabolic treatment of postmenopausal osteoporosis.
    Lyritis GP; Georgoulas T; Zafeiris CP
    Ann N Y Acad Sci; 2010 Sep; 1205():277-83. PubMed ID: 20840284
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy: the Holy Grail for the treatment of postmenopausal osteoporosis?
    Lewiecki EM
    Curr Med Res Opin; 2011 Jul; 27(7):1493-7. PubMed ID: 21668289
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.